JY
FTXH icon

Jeff Yass’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Jeff Yass’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,844
Closed -$201K – 13768
2026
Q1 		$201K Buy
+5,844
New +$200K ﹤0.01% 11695
2025
Q1 		– Sell
-47,518
Closed -$1.28M – 12808
2024
Q4 		$1.28M Buy
47,518
+4,252
+10% +$119K ﹤0.01% 6356
2024
Q3 		$1.25M Buy
43,266
+19,188
+80% +$549K ﹤0.01% 6307
2024
Q2 		$656K Buy
24,078
+6,162
+34% +$165K ﹤0.01% 7587
2024
Q1 		$502K Sell
17,916
-13,712
-43% -$378K ﹤0.01% 8508
2023
Q4 		$842K Buy
31,628
+19,444
+160% +$490K ﹤0.01% 7404
2023
Q3 		$312K Sell
12,184
-28,917
-70% -$765K ﹤0.01% 9267
2023
Q2 		$1.08M Buy
41,101
+474
+1% +$12.5K ﹤0.01% 6510
2023
Q1 		$1.06M Buy
40,627
+31,172
+330% +$835K ﹤0.01% 6655
2022
Q4 		$259K Buy
+9,455
New +$252K ﹤0.01% 9461
2022
Q3 		– Sell
-24,675
Closed -$652K – 13505
2022
Q2 		$652K Sell
24,675
-27,373
-53% -$724K ﹤0.01% 7616
2022
Q1 		$1.39M Buy
52,048
+24,178
+87% +$624K ﹤0.01% 6339
2021
Q4 		$755K Sell
27,870
-28,296
-50% -$743K ﹤0.01% 8039
2021
Q3 		$1.44M Buy
56,166
+16,125
+40% +$423K ﹤0.01% 6601
2021
Q2 		$1.04M Buy
40,041
+19,814
+98% +$512K ﹤0.01% 7668
2021
Q1 		$516K Sell
20,227
-16,051
-44% -$421K ﹤0.01% 9386
2020
Q4 		$935K Buy
36,278
+20,424
+129% +$508K ﹤0.01% 6871
2020
Q3 		$379K Sell
15,854
-8,929
-36% -$214K ﹤0.01% 8250
2020
Q2 		$567K Sell
24,783
-7,522
-23% -$167K ﹤0.01% 7111
2020
Q1 		$644K Buy
+32,305
New +$704K ﹤0.01% 6393
2019
Q2 		– Sell
-26,559
Closed -$568K – 10411
2019
Q1 		$568K Buy
+26,559
New +$552K ﹤0.01% 6029
2017
Q4 		– Sell
-56,488
Closed -$1.13M – 9449
2017
Q3 		$1.13M Buy
56,488
+33,811
+149% +$682K ﹤0.01% 5058
2017
Q2 		$469K Buy
+22,677
New +$457K ﹤0.01% 6761

Other funds holding FTXH

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
MIM
Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
NP
Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's FTXH Position: Q2 2026 in Review

Jeff Yass sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q2 2026, closing a stake of 5,844 shares — an estimated $201K sold.

Jeff Yass first reported a position in FTXH in Q2 2017 and held it in 23 quarters. The position peaked at $1.44M in Q3 2021. 31 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

  • Jeff Yass reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 5,844 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $201K.
  • Jeff Yass first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q2 2017 and held it in 23 quarters.
  • Jeff Yass's First Trust Nasdaq Pharmaceuticals ETF position peaked at $1.44M in Q3 2021.
  • 31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.